Trexquant Investment LP Invests $382,000 in Abeona Therapeutics Inc (NASDAQ:ABEO)

Trexquant Investment LP acquired a new position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 68,516 shares of the biopharmaceutical company’s stock, valued at approximately $382,000. Trexquant Investment LP owned approximately 0.16% of Abeona Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in shares of Abeona Therapeutics during the third quarter worth $84,000. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics during the 3rd quarter valued at about $151,000. XTX Topco Ltd purchased a new stake in Abeona Therapeutics in the third quarter valued at about $160,000. JPMorgan Chase & Co. boosted its holdings in Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 28,606 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Abeona Therapeutics during the fourth quarter worth about $520,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ABEO. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday, March 24th. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective for the company. Finally, StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 24th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Insider Buying and Selling at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $4.78, for a total transaction of $119,500.00. Following the sale, the chief executive officer now directly owns 1,355,322 shares of the company’s stock, valued at $6,478,439.16. This trade represents a 1.81 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 33,000 shares of company stock worth $161,420. Insiders own 5.40% of the company’s stock.

Abeona Therapeutics Stock Performance

ABEO opened at $4.60 on Monday. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a 12-month low of $3.05 and a 12-month high of $8.45. The firm has a 50 day moving average of $5.21 and a two-hundred day moving average of $5.71. The firm has a market capitalization of $223.26 million, a PE ratio of -1.71 and a beta of 1.71.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.19. On average, analysts anticipate that Abeona Therapeutics Inc will post -1.16 EPS for the current year.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.